• James E. Callaway, Ph.D.

    James E. Callaway, Ph.D.

    Chief Executive Officer

    Dr. Callaway has more than 30 years of biopharmaceutical experience, during which he has filed and defended numerous New Drug Applications (NDAs) and Investigational New Drug (IND) Applications. Before joining ArmaGen in December 2012, he served as President and CEO of Cebix Inc., a biopharmaceutical company focused on the treatment of long-term complications of diabetes. Prior to that, he filled several executive roles during his thirteen-year tenure at Elan Pharmaceutical, including Program Executive for the Alzheimer’s Immunotherapy program encompassing five pipeline candidates including bapinuzumab, and Vice President Biopharmaceutical Development Services. During his tenure at Elan, he led the approval of MyoBloc® and the production of Tysabri®. Prior to Elan, Dr. Callaway held development responsibilities at Bayer Pharmaceuticals, SmithKline Beecham (GSK) as well as Ingene (Xoma). Dr. Callaway received his Ph.D. in biological chemistry from the University of California (UCLA) with a focus on peptide chemistry.

  • William M. Pardridge, M.D.

    William M. Pardridge, M.D.

    Founder and Chief Scientific Officer

    Dr. Pardridge formed ArmaGen in 2003 and supported the company the first 10 years with $20 million in non-dilutive funding. Dr. Pardridge, who is a Distinguished Professor Emeritus, UCLA, is a recognized leader in blood-brain barrier (BBB) research. He has focused on the area since 1970, and is credited with inventing the antibody directed receptor-mediated transcytosis technology, the liposome technology for non-viral, non-invasive gene therapy of the brain, and the field of BBB genomics. He is the author of over 500 publications, more than 450 of which focus on the BBB. Dr. Pardridge is board certified in Internal Medicine, and Endocrinology and Metabolism.

  • Ruben Boado, Ph.D.

    Ruben Boado, Ph.D.

    Vice President of Research and Development

    Dr. Boado co-founded ArmaGen in 2004, following more than 25 years of academic experience in fields of molecular and cell biology of the BBB, and drug delivery to the brain. His leadership and expertise have been instrumental in the development of ArmaGen’s extensive product pipeline, including potential biotherapeutic treatments for mucopolysaccharidosis, stroke, Alzheimer’s disease and Parkinson’s disease. Dr. Boado was the principal investigator in a number of Small Business Innovation Research (SBIR) programs granted by the National Institutes of Health to ArmaGen. Dr. Boado is also a co-inventor of the intellectual property that supports ArmaGen’s pipeline. He was previously professor of Medicine at UCLA, and has published over 195 scientific peer-reviewed publications and book chapters related to the BBB. Dr. Boado received his Ph.D. in Biochemistry at the University of Buenos Aires.

  • Rioux2

    Patrice Rioux, M.D., Ph.D.

    Senior Vice President of Global Clinical Development

    Dr Rioux joined ArmaGen in July 2015. His career in clinical drug development spans nearly four decades, during which time he gained extensive experience as a clinician, researcher, medical director and regulatory specialist. His background includes development of drugs and biologic products for various indications across neurodegenerative diseases, immunology, pain management, oncology and metabolic diseases. He was most recently Chief Medical Officer at Raptor Pharmaceuticals, Inc. where he was responsible for securing regulatory approval of a delayed-release cysteamine for the treatment of a lysosomal storage disease, nephropathic cystinosis, in both the U.S. and Europe. He previously served as Chief Medical Officer at Ferrokin Biosciences and Edison Pharmaceuticals, and as Vice President Clinical at Repligen, where he gained significant orphan disease experience in Huntington’s, mitochondrial diseases, autism, Parkinson’s disease and nonalcoholic steatohepatitis (NASH). He has also held senior roles Biogen, Arrow International, Variagenics, Inc., and GRP (Groupement de Recherche en Pharmacologie), and has consulted for Glaxo, SmithKline Beecham, Pfizer, Bristol-Myers Squibb and Lilly. Dr. Rioux received his Medical Education at Faculte de Medecine Pitie-Salpetriere, his Ph.D in Mathematical Statistics at Faculte des Sciences, and his Degree of Pharmacology (pharmacokinetics and clinical pharmacology) at Faculte de Medecine Pitie-Salpetriere.

  • Derek Kelaita, M.B.A.

    Derek Kelaita, MBA

    Vice President, Business Development

    Mr. Kelaita has more than 15 years of business/corporate development experience negotiating in-licensing, out-licensing transactions as well as strategic collaborations for public/private biopharmaceutical companies. He has been responsible for licensing/M&A transactions valued at over $1 billion in multiple therapeutic areas including: orphan drugs (ArmaGen), immunotherapy (AnaptysBio), metabolic/diabetes (Cebix), dental (Novalar), infectious disease (Nventa), oncology (Dendreon) and cardiovascular disease (Corvas). Mr. Kelaita brings to ArmaGen a history of successfully directing cross-functional teams of senior executives to achieve business development objectives and provides strategic and tactical advice in the areas of corporate/business development, investor relations, public relations, intellectual property, finance and market research.